Read this company snapshot
Daily valuation snapshot
Legend Biotech Corporation American Depositary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $18.62
- Market capitalization (USD)
- $3,443,642,095.39
- Price / earnings (TTM)
- Not reported
- Price / book
- 3.44
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research LEGN in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research LEGN in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing LEGN with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $18.62 |
| Market capitalization (USD) | $3,443,642,095.39 |
| Price / earnings (TTM) | Not reported |
| Price / book | 3.44 |
No matching rows. Clear the filter to see all records.
Read LEGN's valuation metrics
Company size
Legend Biotech Corporation American Depositary Shares's recorded market capitalization is $3,443,642,095.39. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
LEGN's recorded price-to-book ratio is 3.44. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Legend Biotech Corporation American Depositary Shares with Aurora
Use the snapshot above to ask a specific question about LEGN. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow LEGN's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.